XOMA Corp XOMAP:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/01/21 EST
25.57quote price arrow up+0.11 (+0.44%)
Volume
3,318
52 week range
23.69 - 25.80

...

Loading . . .

KEY STATS

  • Open25.33
  • Day High25.60
  • Day Low25.33
  • Prev Close25.57
  • 52 Week High25.80
  • 52 Week High Date02/03/21
  • 52 Week Low23.69
  • 52 Week Low Date12/21/20
  • Market Cap399M
  • Shares Out11.02M
  • 10 Day Average Volume0.00M
  • Dividend2.16
  • Dividend Yield8.43%
  • Beta
  • 1 Year % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest XOMA Corp News

There is no recent news for this security.

Latest XOMAP News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting...
W. Denman Van Ness
Chairman
James Neal
Chief Executive Officer
Thomas Burns
Chief Financial Officer
Address
2200 Powell St Ste 310
Emeryville, CA
94608-1818
United States